Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 05, 2023 10:04am

150 Views

Post# 35480225

RE:Conditions are right for biopharma M&A to break out

" Raghav Mittal, assistant director at research firm Acuity Knowledge Partners, said in an email that acquisitions of biotech companies working on oncology or immunology treatments could be worth $5 billion to $25 billion a pop."

Well it appears that biotech analysts now view Big Pharm's M&A "sweet spot" as expanding to US$25 Billion.

Consequently ONCY'S acquisition value at US$10 Billion to US$15 Billion has become a very real proposition.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing